These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30411692)

  • 1. Report of Adverse Events in Colombia: A Successful Case.
    Moreno-Mattar O; Ramírez R; Alvarado A; Sierra F; Guzmán J
    Curr Drug Saf; 2019; 14(1):53-56. PubMed ID: 30411692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases.
    Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA
    Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fifty years of pharmacovigilance - Medicines safety and public health.
    Laporte JR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):725-32. PubMed ID: 26799344
    [No Abstract]   [Full Text] [Related]  

  • 5. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance - The next chapter.
    Moore N; Berdaï D; Blin P; Droz C
    Therapie; 2019 Dec; 74(6):557-567. PubMed ID: 31623850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
    Kant A; de Vries L; Rolfes L
    Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance Programme of India: Recent developments and future perspectives.
    Kalaiselvan V; Thota P; Singh GN
    Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fifteen years of patient reporting -what have we learned and where are we heading to?
    van Hunsel F; Härmark L; Rolfes L
    Expert Opin Drug Saf; 2019 Jun; 18(6):477-484. PubMed ID: 31030578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
    Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
    Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
    Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
    J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canada's Adverse Drug Reaction Reporting System: A Failing Grade.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2015; 22(2):e167-72. PubMed ID: 26590356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of a new pharmacovigilance tool: Simplified online reporting for general practitioners].
    Humbert X; Chrétien B; Sassier M; Coquerel A; Alexandre J; Fedrizzi S
    Sante Publique; 2018; 30(2):225-232. PubMed ID: 30148310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Beyzarov E; Chen Y; Julg R; Naim K; Shah J; Gregory WW; Ayoub A; Caubel P
    Drug Saf; 2021 Jan; 44(1):95-105. PubMed ID: 33354753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.